CLEOPATRA: Treating HER2-Positive Breast Cancer

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast CancerПодробнее

Highlights of the 2023 San Antonio Breast Cancer Symposium With Jason Mouabbi, MDПодробнее

PD8 Spotlight Session 8 HER2 Positive Breast CancerПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Early response and long-term outcomes in the CLEOPATRA trialПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

Medical update: HER2-Positive and triple-positive metastatic breast cancerПодробнее

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast ConferenceПодробнее

Treatment for Metastatic HER2-Positive Breast Cancer. Raul G. Ramírez, MDПодробнее

Management of HER2 positive metastatic breast cancer treatment algorithmПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

CLEOPATRA & EMILIA: HER2+ mBC state-of-the-artПодробнее

Changing landscape in the management of HER2 positive locally advanced and metastatic breast cancerПодробнее

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее

T-DXd; DS-8201a in subjects with HER2-positive metastatic breast cancer previously treated with ...Подробнее

Treatments for Relapsed/Refractory HER2+ Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее